Paradigm secures USD $27M to fully fund its global Phase 3 OA trial through interim analysis. Join today’s investor webinar at 11:30 am AEST: https://t.co/np4s7y4q6x

Today, Paradigm Biopharmaceuticals announced the acquisition of Proteobioactives, securing global rights to a patented oral combination of PPS and a COX-2 inhibitor, targeting early-stage osteoarthritis in both humans and animals. Read more here:

This stock could have something close to a cure for #osteoarthritis. Don’t let it hide under your nose Paradigm Biopharmaceuticals (#ASX: $PAR) Managing Director Paul Rennie spoke with The Market Online to discuss further > Find out more: https://t.co/twTnIGarz6 @ParadigmBio

We’ve secured centralised US ethics approval for our Phase 3 trial of iPPS in knee osteoarthritis. A significant step in expanding our clinical program and advancing a first-in-class treatment for millions. See Paul Rennie’s comments & full ASX release: https://t.co/onjksDe54e

We're hiring! Paradigm is looking for a Clinical Operations Lead (Hybrid) to manage global trials for our ASX-listed biotech. Apply now 👉 https://t.co/cm94aYJr6r #BiotechJobs #ClinicalResearch #Hiring #ASX $PAR #PharmaCareers #RemoteWork

Last week, Paradigm presented at the Ignite Investment Summit in Hong Kong. We had incredible engagement from leading family offices across Asia. The strong interest in our phase 3 OA program reaffirms Paradigm as a standout late-stage biotech opportunity. #IgniteConference

Paradigm clear to proceed to our pivotal phase three clinical trial in knee osteoarthritis. This is a significant milestone for the company. The team now shifts their focus to the start-up activities to initiate patient enrolment. Read more:

Did you catch Tim Boreham's recent article on Paradigm?

Break it Down: Paradigm Biopharmaceuticals en route to Phase 3 clinical trial with FDA support https://t.co/Kq7a38OQe1 #ASX #ASX200 $PAR @ParadigmBio

This is a significant milestone for Paradigm. You can read more at the link below. https://t.co/eBwPRm7rbP

The FDA's feedback on our phase 2 clinical data confirms the safety and tolerability of our dosing regimen (2mg/kg iPPS administered twice weekly). It offers a clear pathway to move forward with the pivotal phase 3 trial. 2/3

We are pleased to announce a positive response from the U.S. FDA. 1/3

Paradigm's 2024 Annual Report has been released. Key Highlights: - iPPS shows 12-month efficacy - Structural improvements seen at six months - PARA_OA_002 Stage 1 completed Read the full report:

Founder and MD, Paul Rennie, presented Paradigm's clinical progress and exciting data to the Bioshares Biotech Summit in Fremantle last week. We would like to thank Mark Pachacz and the wider Bioshares team for the opportunity to present and an outstanding conference. $PAR #ASX

Managing Director, Paul Rennie, will be presenting at the upcoming 18th Bioshares Biotech Summit on Friday 12 July, in Fremantle, Western Australia. $PAR #KneeOA #osteoarthritis #pentosan #PPS

#ASX #biotech companies are gunning for US #FDA approval as that not only validates the safety and efficacy of a new drug, but also offers commercial opportunities.

Today, we celebrate the achievements of women worldwide, including the incredible contributions of the women at Paradigm. Your dedication is helping to shape the future of care for those suffering from osteoarthritis. Thank you for your invaluable impact on the organisation.

Arthritis Australia's Senate Inquiry appearance in Feb, spotlighted challenges faced by arthritis patients amid rising costs. CEO Jonathan Smithers stressed staggering out-of-pocket expenses, urging for change and new treatments. Read more: https://t.co/tux5clzpv6 $PAR

Today Paradigm received a $7.36 million tax incentive refund. Read more here:

We acknowledge that investors may seek additional clarification regarding this announcement. Kindly direct any inquiries to the following email address: investorrelations@paradigmbiopharma.com